Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Kisspeptin

Kisspeptin

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 11 September 2026

Genuinely one of the better human-trial-backed compounds we cover — real controlled trials on ovulation triggering and on brain activity tied to sexual desire. Almost none of that trial evidence has anything to do with how it's marketed to consumers.

On this page
  1. What it is
  2. What the trial evidence shows
  3. The gap between the trials and the consumer product

In brief

Should you care? This is a case where real, peer-reviewed human trial evidence exists — more of it than for almost anything else we cover — but it comes from specialist reproductive-endocrinology research, not from anything resembling a consumer libido product.

The short version

  • Real, published, controlled human trials from a credible academic research group (Imperial College London).
  • Two distinct applications studied: triggering egg maturation in IVF, and brain activity linked to sexual/emotional processing.
  • Not an approved product — administered as IV/subcutaneous infusion, in monitored research settings, not as a consumer supplement.

What it is

Kisspeptin is the peptide product of the KISS1 gene — the body's own master regulator of the reproductive hormone axis (GnRH/LH secretion). Kisspeptin-54 is the major circulating human form, and the one used in the trials below.

What the trial evidence shows

Jayasena et al. (J Clin Invest 2014;124(8):3667-3677, PMID 25036713) gave a single subcutaneous injection of kisspeptin-54 to 53 women undergoing IVF, triggering final oocyte maturation at every dose tested, as an alternative to conventional triggers. Comninos et al. (J Clin Invest 2017;127(2):709-719, PMID 28112678) gave IV kisspeptin to 29 healthy men in a double-blind, placebo-controlled trial and found it enhanced limbic-system brain activity during sexual and romantic-bonding imagery, with measured improvements on behavioral and mood scales — the first controlled human demonstration that kisspeptin modulates sexual brain processing. Both are real, peer-reviewed, controlled trials from the same Imperial College London reproductive endocrinology research group.

The gap between the trials and the consumer product

Consumer "kisspeptin" products — nasal sprays, injectable vials sold for libido or hormone balance — bear no real relationship to the controlled infusion protocols, exact doses, or monitored clinical settings the trials above actually used. It is not an approved drug for any use, and remains investigational, administered only under research protocols. This is a case where unusually solid trial evidence exists, but doesn't remotely resemble how the compound reaches consumers — worth holding both facts at once rather than letting one stand in for the other.

References

  1. Jayasena et al., "Kisspeptin-54 Triggers Egg Maturation in Women Undergoing In Vitro Fertilization," J Clin Invest 2014;124(8):3667-3677, PMID 25036713.
  2. Comninos et al., "Kisspeptin Modulates Sexual and Emotional Brain Processing in Humans," J Clin Invest 2017;127(2):709-719, PMID 28112678.